GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…
Biotechnology
CH, Plan-les-Ouates [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -100.00 | -4.44 | 0.00 | |
| Graham Fair Price | 100.00 | 2.00 | 0.00 | |
| PEG | 0.00 | 0.00 | 0.00 | |
| Price/Book | -100.00 | -1.96 | 0.00 | |
| Price/Cash Flow | -100.00 | -4.99 | 0.00 | |
| Prices/Earnings | -100.00 | -0.86 | 0.00 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | -100.00 | -4.99 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | n.A. | -1.25 | n.A. | |
| ROE | n.A. | 0.57 | n.A. | |
| ROIC | n.A. | 1.11 | n.A. | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | 0.00 | 0.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.00 | 0.00 | 0.00 | |
| EPS QOQ | 0.00 | 0.00 | 0.00 | |
| FCF QOQ | 0.00 | 0.00 | 0.00 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 1.76 | -1.10 | -37.65 | |
| Quick Ratio | 1.59 | 0.32 | -79.92 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | -0.56 | -100.00 | |
| Cash | 0.00 | 0.07 | 100.00 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 0.00 | -0.22 | -100.00 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad